Browsing Tag
pharmaceutical M&A
8 posts
Can pharma M&A survive Australia’s new national interest doctrine?
Australia’s FIRB blocked Cosette’s $430M takeover of Mayne Pharma. Can foreign pharma buyers still close deals in this new national interest era?
Pfizer sweetens Metsera acquisition offer to secure board approval and fend off Novo Nordisk challenge
Find out how Pfizer’s amended $86.25-per-share merger with Metsera reshapes the obesity-drug race and signals Big Pharma’s shifting acquisition strategy.
Evoke Pharma stock surges 130% as QOL Medical signs definitive $11-per-share acquisition agreement
Find out how Evoke Pharma’s $11-per-share acquisition by QOL Medical is reshaping specialty pharma and why investors are applauding this record premium.
Merger war explodes: Pfizer drags Metsera and Novo Nordisk to court over ‘illegal’ bid
Pfizer takes legal action against Metsera and Novo Nordisk over breach of merger terms. Find out how this battle could reshape obesity drug M&A.
Pfizer thought it secured Metsera—then Novo Nordisk crashed the party with a bigger bid
Novo Nordisk just challenged Pfizer’s Metsera deal with a $9B rival bid. Find out how this could reshape the weight-loss drug landscape in 2025.
From GLP-1 to FGF21: How Novo Nordisk’s Akero Therapeutics deal signals a new era in metabolic drug dominance
Novo Nordisk’s $5.2 B Akero deal adds the FGF21 drug efruxifermin to its MASH portfolio. See how it expands the company’s metabolic dominance.
Mallinckrodt secures Irish High Court approval for Endo merger, positioning scaled therapeutics leader for August 2025 closing
Mallinckrodt gains Irish High Court approval for its Endo merger, expected to close in August 2025. Analysts see scaled growth in specialty therapeutics.
Torrent Pharmaceuticals to acquire J. B. Chemicals from KKR in INR 25,689 Cr deal: M&A to strengthen CDMO, IPM presence
Torrent Pharmaceuticals to acquire JB Pharma from KKR in INR 25,689 crore deal, followed by merger; aims to expand CDMO and India chronic segment leadership.